ANG Lifesciences India Ltd

ANG Lifesciences India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

ANG Lifesciences India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 29 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Surging past its previous peaks, ANG Lifesciences India Ltd reached a fresh 52-week high of Rs 49.69 on 25 Jun 2026, marking a remarkable rally of 73.68% over the past year against the Sensex’s decline of 6.33%. This milestone caps a three-day winning streak that has delivered a 62.24% return, fuelled by a confluence of strong technical signals and sustained price momentum.

With a surge to Rs 41.41 on 24 Jun 2026, ANG Lifesciences India Ltd has reached a fresh 52-week high, marking a 46.74% gain over the past year and significantly outperforming the Sensex, which declined 6.28% in the same period. This milestone reflects a powerful alignment of technical indicators and sustained price momentum.

The 50-day moving average has crossed above the 200-day moving average for ANG Lifesciences India Ltd, signalling a golden cross on 18 Jun 2026. Yet, the stock declined 2.55% on the same day, while monthly technical indicators remain only mildly bullish or neutral. This divergence between the moving averages and price action calls for a closer examination of the signal’s reliability.

ANG Lifesciences India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

ANG Lifesciences India Limited reported a net loss of ₹1.38 crores for Q1 FY27 (April-June 2026), narrowing from a ₹4.75 crores loss in the previous quarter. Despite a 25.47% quarter-on-quarter revenue increase to ₹23.50 crores, the Amritsar-based pharmaceutical company continues to grapple with persistent profitability challenges that have plagued operations for over three years. The stock surged 7.84% to ₹29.45 following the results announcement, though the micro-cap company's market capitalisation remains modest at ₹38.46 crores.

ANG Lifesciences India Ltd has demonstrated a notable improvement in its financial performance for the quarter ended March 2026, reversing a previously negative trend. The company’s revenue growth, margin expansion, and profitability metrics have all shown encouraging signs, signalling a potential shift in its operational trajectory despite ongoing market challenges.

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Jun 2023. However, the analysis and financial metrics discussed here reflect the company’s current position as of 27 May 2026, providing investors with the latest insights into its performance and outlook.

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Jun 2023. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Jun 2023. However, the analysis and financial metrics discussed here reflect the company’s current position as of 28 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 June 2023. However, the analysis and financial metrics discussed below reflect the company’s current position as of 16 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

For the seventh consecutive session, ANG Lifesciences India Ltd has closed lower, culminating in a fresh 52-week low of Rs 17.63 on 30 Mar 2026. This sustained decline has erased 16.85% of the stock’s value over the past week, signalling persistent selling pressure amid a challenging market backdrop.

For the sixth consecutive session, ANG Lifesciences India Ltd has closed lower, culminating in a fresh 52-week low of Rs 18.5 on 27 Mar 2026. This marks a 15.98% decline over this losing streak, underscoring persistent selling pressure amid broader market weakness.

ANG Lifesciences India Ltd’s stock price declined to a fresh 52-week low of Rs.19 on 25 March 2026, marking a significant milestone in the company’s ongoing downward trajectory. This new low comes amid a series of consecutive losses and reflects persistent challenges faced by the pharmaceutical and biotechnology firm.

For the fourth consecutive session, ANG Lifesciences India Ltd has closed lower, culminating in a fresh 52-week low of Rs 19.51 on 24 Mar 2026. This marks a significant 50.9% decline from its 52-week high of Rs 39.7, underscoring persistent selling pressure amid challenging fundamentals and market headwinds.